Semaglutide is a modified GLP-1 analogue with receptor-level research and substantial human trial evidence for specific weight-related and cardiovascular outcomes.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
GLP-1 receptor agonist
Semaglutide is a peptide analogue of glucagon-like peptide-1. Its molecular design incorporates amino-acid substitutions and a fatty-acid-containing side chain to alter stability and albumin binding. Research into the molecule spans medicinal chemistry and controlled trials of defined pharmaceutical formulations.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
Semaglutide activates the GLP-1 receptor, connecting a peptide signal with metabolic and appetite-regulating pathways. Discovery studies optimized the balance between receptor activity and prolonged exposure through albumin association. Molecular persistence is a pharmacological property, not evidence that independently sourced materials behave like the clinical product.
The discovery paper describes modifications intended to preserve GLP-1 receptor activity while increasing albumin affinity and resistance to metabolic degradation. These experiments help explain why sequence and chemical modifications matter when comparing peptide analogues. [1]
STEP 1 randomized 1,961 adults with overweight or obesity without diabetes. Semaglutide, alongside lifestyle intervention, produced greater average weight reduction than placebo. Gastrointestinal events contributed to treatment discontinuation and are part of the result, not incidental to efficacy. [2]
SELECT studied people with established cardiovascular disease and overweight or obesity without diabetes. The trial found fewer major cardiovascular events with semaglutide than placebo. Its population and clinical endpoints are distinct from a general weight-loss study or primary-prevention claim. [3]
Study topics describe the cited models, not established benefits of this catalog material.
The cited human studies evaluate both a body-weight endpoint and a major clinical-event endpoint, providing different kinds of evidence. Their conclusions apply to the enrolled populations, follow-up and pharmaceutical preparations studied; they should not be generalized to every proposed research use.
Average trial effects do not predict an individual's outcome, and tolerability can affect persistence and interpretation. Receptor activity alone cannot establish formulation equivalence. These references do not verify WYZ identity, purity, sterility or manufacturing, and do not support using a research material as a substitute for a clinical product.
Primary studies and clearly identified supporting sources. Each link opens the original record.
Molecular modifications, receptor activity and albumin-binding optimization.
STEP 1 randomized trial in adults without diabetes.
SELECT cardiovascular outcomes in participants with established cardiovascular disease.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAOther single compounds in the collection.
Metabolic Research
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Metabolic Research
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Dermal Research
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
